Tailoring antiviral therapy in hepatitis C

Tailoring the length of antiviral treatment for hepatitis C.

http://gut.bmj.com/content/59/01/1.full.html Updated information and services can be found at: These include: References http://gut.bmj.com/content/59/01/1.full.html#ref-list-1 This article cites 36 articles, 5 of which can be accessed free at: service Email alerting box at the top right corner of the online article. Receive free email alerts when new articles cite this article. Sign up in the ...

Targets for antiviral therapy of hepatitis C.

Presently, interferon- (IFN-) containing treatment regimens are the standard of care for patients with hepatitis C virus (HCV) infections. Although this therapy eliminates the virus in a substantial proportion of patients, it has numerous side effects and contraindications. Recent approval of telaprevir and boceprevir, targeting the protease residing in nonstructural protein 3 (NS3) of the HCV ...

New treatment of hepatitis C (Direct Acting Antiviral)

Hepatitis C virus (HCV) infection is a major cause of chronic liver disease, with approximately 71 million chronically infected individuals worldwide. Clinical care for the patients with HCV-related liver disease has advanced considerably thanks to an enhanced understanding of the pathophysiology of the disease, and because of developments in diagnostic procedures and improvements in therapy an...

Antiviral Therapy in Elderly Patients With Hepatitis C Virus Infection.

The emergence of direct-acting antiviral (DAA) agents has revolutionized the treatment schema for hepatitis C virus (HCV) infection. From cure rates to tolerability, DAA agents have shown outstanding profiles compared with the prior therapy of pegylated interferon with ribavirin. However, the efficacy and safety profiles of DAA therapy in older patients, particularly the elderly, have been uncl...

Antiviral therapy of recurrent hepatitis C in liver transplantation.